Development of an ectopic huLiver model for Plasmodium liver stage infection
Issued Date
2023-03-01
Resource Type
eISSN
19326203
Scopus ID
2-s2.0-85150281343
Pubmed ID
36928885
Journal Title
PLoS ONE
Volume
18
Issue
3 March
Rights Holder(s)
SCOPUS
Bibliographic Citation
PLoS ONE Vol.18 No.3 March (2023)
Suggested Citation
Samayoa-Reyes G., Flaherty S.M., Wickham K.S., Viera-Morilla S., Strauch P.M., Roth A., Padrón L., Jackson C.M., Meireles P., Calvo D., Roobsoong W., Kangwanrangsan N., Sattabongkot J., Reichard G., Lafuente-Monasterio M.J., Rochford R. Development of an ectopic huLiver model for Plasmodium liver stage infection. PLoS ONE Vol.18 No.3 March (2023). doi:10.1371/journal.pone.0279144 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82144
Title
Development of an ectopic huLiver model for Plasmodium liver stage infection
Other Contributor(s)
Abstract
Early Plasmodium falciparum and P. vivax infection requires parasite replication within host hepatocytes, referred to as liver stage (LS). However, limited understanding of infection dynamics in human LS exists due to species-specificity challenges. Reported here is a reproducible, easy-To-manipulate, and moderate-cost in vivo model to study human Plasmodium LS in mice; the ectopic huLiver model. Ectopic huLiver tumors were generated through subcutaneous injection of the HC-04 cell line and shown to be infectible by both freshly dissected sporozoites and through the bite of infected mosquitoes. Evidence for complete LS development was supported by the transition to blood-stage infection in mice engrafted with human erythrocytes. Additionally, this model was successfully evaluated for its utility in testing antimalarial therapeutics, as supported by primaquine acting as a causal prophylactic against P. falciparum. Presented here is a new platform for the study of human Plasmodium infection with the potential to aid in drug discovery.